Evelyn Degenhard

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Hermann Einsele, Carsten Reinhardt, Thomas Burmeister, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

H. Einsele, P. Kufer, P. Baeuerle, 2012, Blood.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Andreas Wolf, Dirk Nagorsen, Monika Brüggemann, 2012, Blood.

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

G. Zugmaier, H. Horst, R. Bargou, 2014, Blood Cancer Journal.

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

P. Kufer, P. Baeuerle, M. Schmid, 2008 .

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

H. Einsele, L. Kanz, A. Mackensen, 2011 .

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE®) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

M. Pfreundschuh, M. Libicher, G. Hess, 2014 .